SOMERSET, N.J. & GOSSELIES, Belgium–(BUSINESS WIRE)–Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, and MaSTherCell Global, Inc., a technology-focused cell and gene therapy contract development and manufacturing organization to leading cell therapy innovators, today announced that Catalent has agreed to acquire MaSTherCell Global, a company backed by Great Point Partners, SFPI-FPIM, and Orgenesis Inc. (NASDAQ:ORGS), for an aggregate of $315 million in cash, subject to a customary adjustments.
{iframe}https://biobuzz-io.cdn.ampproject.org/c/s/biobuzz.io/catalent-to-acquire-leading-cell-therapy-company-masthercell-global-for-315-million-from-germantown-marylands-orgenesis-inc/amp/{/iframe}